 |
| |
 |
| |
 |
| |
 |
| |
 |
| _____________________________________________________________________________________________________________________ © 2005-11 All Rights Reserved. NOD Pharmaceuticals, Inc. |
the closing of series A private financing. BioVeda Capital, a venture capital firm based in Redwood
City, is the sole investor of this preferred equity financing.
"The proceeds from series A funding will be used to fund our wholly owned subsidiary in China to
develop our leading products, oral insulin and oral interferon," William Lee, CEO of NOD
Pharmaceuticals, Inc., explains.
Oral insulin and oral interferon are developed with nano-particle oral delivery or NOD technology
and are being developed first in China to take advantages of the lower cost and short development
cycle in China.
NOD technology uses nano-partilces as carrier to efficiently deliver bio-active macromolecular drugs
such as insulin or interferon via oral route.
This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state.
NOD Pharmaceuticals, Inc. is a biopharmaceutical company focusing on innovative drug delivery.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., +1-858-457-0899
www.nodpharm.com
info@nodpharm.com
City, is the sole investor of this preferred equity financing.
"The proceeds from series A funding will be used to fund our wholly owned subsidiary in China to
develop our leading products, oral insulin and oral interferon," William Lee, CEO of NOD
Pharmaceuticals, Inc., explains.
Oral insulin and oral interferon are developed with nano-particle oral delivery or NOD technology
and are being developed first in China to take advantages of the lower cost and short development
cycle in China.
NOD technology uses nano-partilces as carrier to efficiently deliver bio-active macromolecular drugs
such as insulin or interferon via oral route.
This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state.
NOD Pharmaceuticals, Inc. is a biopharmaceutical company focusing on innovative drug delivery.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., +1-858-457-0899
www.nodpharm.com
info@nodpharm.com
Press Release
| NOD Pharmaceuticals, Inc. closes series A financing |
 |  |  |
-Innovation Delivered